L Acarin1, B González, B Castellano. 1. Unit of Histology, School of Medicine, Department of Cell Biology, Physiology, and Immunology, Autonomous University of Barcelona, Bellaterra, Spain. lacarin@servet.uab.es
Abstract
BACKGROUND AND PURPOSE: Nuclear factor-kappaB (NF-kappaB) and the signal transducer and activator of transcription 3 (STAT3) are important transcription factors regulating inflammatory mechanisms and the glial response to neural injury, determining lesion outcome. In this study we evaluate the ability of triflusal (2-acetoxy-4-trifluoromethylbenzoic acid), an antiplatelet agent inhibitor of NF-kappaB activation, to improve lesion outcome after excitotoxic damage to the immature brain. METHODS: Postnatal day 9 rats received an intracortical injection of the excitotoxin N-methyl-D-aspartate (NMDA) and oral administration of triflusal (30 mg/kg) either as 3 doses before NMDA injection (pretreatment) or as a single dose 8 hours after NMDA injection (posttreatment). After survival times of 10 and 24 hours, brains were processed for toluidine blue staining, tomato lectin histochemistry, and glial fibrillary acidic protein, NF-kappaB, and STAT3 immunocytochemistry. RESULTS: NMDA-lesioned animals that were not treated with triflusal showed activation of NF-kappaB in neuronal cells at first and in glial cells subsequently. Animals that received pretreatment with triflusal showed a strong downregulation of neuronal and glial NF-kappaB but a similar development of the glial response and an equivalent lesion volume compared with nontreated animals. In contrast, animals receiving triflusal posttreatment showed increased early neuronal NF-kappaB but a reduction in the subsequent glial NF-kappaB, accompanied by important downregulation of the microglial and astroglial response and a drastic reduction in the lesion size. STAT3 activation was not affected by triflusal treatment. CONCLUSIONS: Triflusal posttreatment diminishes glial NF-kappaB, downregulates the glial response, and improves the lesion outcome, suggesting a neuroprotective role of this compound against excitotoxic injury in the immature brain.
BACKGROUND AND PURPOSE: Nuclear factor-kappaB (NF-kappaB) and the signal transducer and activator of transcription 3 (STAT3) are important transcription factors regulating inflammatory mechanisms and the glial response to neural injury, determining lesion outcome. In this study we evaluate the ability of triflusal (2-acetoxy-4-trifluoromethylbenzoic acid), an antiplatelet agent inhibitor of NF-kappaB activation, to improve lesion outcome after excitotoxic damage to the immature brain. METHODS: Postnatal day 9 rats received an intracortical injection of the excitotoxin N-methyl-D-aspartate (NMDA) and oral administration of triflusal (30 mg/kg) either as 3 doses before NMDA injection (pretreatment) or as a single dose 8 hours after NMDA injection (posttreatment). After survival times of 10 and 24 hours, brains were processed for toluidine blue staining, tomato lectin histochemistry, and glial fibrillary acidic protein, NF-kappaB, and STAT3 immunocytochemistry. RESULTS:NMDA-lesioned animals that were not treated with triflusal showed activation of NF-kappaB in neuronal cells at first and in glial cells subsequently. Animals that received pretreatment with triflusal showed a strong downregulation of neuronal and glial NF-kappaB but a similar development of the glial response and an equivalent lesion volume compared with nontreated animals. In contrast, animals receiving triflusal posttreatment showed increased early neuronal NF-kappaB but a reduction in the subsequent glial NF-kappaB, accompanied by important downregulation of the microglial and astroglial response and a drastic reduction in the lesion size. STAT3 activation was not affected by triflusal treatment. CONCLUSIONS:Triflusal posttreatment diminishes glial NF-kappaB, downregulates the glial response, and improves the lesion outcome, suggesting a neuroprotective role of this compound against excitotoxic injury in the immature brain.
Authors: M Valle; M J Barbanoj; A Donner; I Izquierdo; U Herranz; N Klein; H G Eichler; M Müller; M Brunner Journal: Eur J Clin Pharmacol Date: 2005-02-12 Impact factor: 2.953
Authors: M Coma; L Serenó; B Da Rocha-Souto; T C Scotton; J España; M B Sánchez; M Rodríguez; J Agulló; C Guardia-Laguarta; M Garcia-Alloza; L A Borrelli; J Clarimón; A Lleó; B J Bacskai; C A Saura; B T Hyman; T Gómez-Isla Journal: Neurobiol Dis Date: 2010-02-10 Impact factor: 5.996
Authors: Jenni Raasch; Nicolas Zeller; Geert van Loo; Doron Merkler; Alexander Mildner; Daniel Erny; Klaus-Peter Knobeloch; John R Bethea; Ari Waisman; Markus Knust; Domenico Del Turco; Thomas Deller; Thomas Blank; Josef Priller; Wolfgang Brück; Manolis Pasparakis; Marco Prinz Journal: Brain Date: 2011-02-10 Impact factor: 13.501
Authors: J A González-Correa; M M Arrebola; I M Ureña; D Ruiz-Villafranca; J Muñoz-Marín; A Guerrero; F Sánchez de la Cuesta; J P De La Cruz Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2004-12-16 Impact factor: 3.000